High-Content and High-Throughput In Vivo Drug Screening Platforms Using Microfluidics

Area of Science:

• Biomedical research
• Drug discovery and development
• Genetics and genomics

Background:

• The drug discovery process is costly, time-consuming, and often fails to yield cures for many human diseases.
• Current drug discovery pipelines require novel approaches to improve efficiency and success rates.
• Whole-animal models offer system-level insights but can be expensive; small animal models present a viable alternative.

Purpose of the Study:

• To review current technologies for developing novel disease models for drug discovery.
• To highlight the utility of small animal models, specifically Caenorhabditis elegans, for large-scale drug testing.
• To present novel high-throughput and high-content screening platforms developed for C. elegans disease models.

Main Methods:

• Review of existing literature on disease models in drug discovery.
• Focus on small animal models, particularly Caenorhabditis elegans, for their physiological relevance and genetic homology.
• Description of two newly developed platforms for high-throughput and high-content screening using C. elegans.

Main Results:

• Small animal models, such as C. elegans, provide a balance of physiological complexity and cost-effectiveness for drug screening.
• High-throughput and high-content screening platforms enhance the efficiency and depth of analysis in C. elegans disease models.
• These advanced screening methods aid in prioritizing drug candidates with improved translational potential.

Conclusions:

• Caenorhabditis elegans serves as a powerful model organism for advancing drug discovery through innovative screening technologies.
• The developed platforms facilitate rapid and comprehensive evaluation of potential drug compounds.
• Implementing such models and technologies can significantly improve the efficiency and success rate of drug discovery pipelines, ultimately reducing healthcare costs.